Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jul 09, 2024 9:45pm
197 Views
Post# 36125568

RE:RE:RE:WSJ Article - courtesy MSN.COM

RE:RE:RE:WSJ Article - courtesy MSN.COM

I would be surprised if Carlyle's analyst teams haven't already crunched some numbers on all aspects of Vantives current and future opportunities including the potential future cash flows from PMX distribution efforts. 

it's a short leap from there for Carlyle's team to ask the question, what if we could own the NA rights to PMX  and not just the distribution piece?  Heck maybe they even approach Toray for a global deal ( Carlyle had a Tokyo office too) 

Especially since we now know that Almeida used to work at Carlyle and Franzi ( now a Spectral Board member ) was/is high up the ranks at Baxter. 

This is looking more like an international grandmaster level chess match, not just an endgame between a couple of schmucks. 


MM 

<< Previous
Bullboard Posts
Next >>